Medical management of polymyalgia rheumatica

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 7, 2010, Pages 1077-1087

  Gonzalez Gay, Miguel A ^a   Agudo, Mario ^a   Martinez Dubois, Cristina ^a   Pompei, Orlando ^a   Blanco, Ricardo ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Bisphosphonates; Giant cell arteritis; Infliximab; Methotrexate; Polymyalgia rheumatica; Prednisolone; Relapses

Indexed keywords

ALENDRONIC ACID; AZATHIOPRINE; CALCIUM; CORTICOSTEROID; DEFLAZACORT; FOLINIC ACID; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; METHYLPREDNISOLONE ACETATE; PARATHYROID HORMONE; PLACEBO; PREDNISOLONE; PREDNISONE; RISEDRONIC ACID; VITAMIN D;

BLOOD VESSEL BIOPSY; CLINICAL FEATURE; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; GIANT CELL ARTERITIS; HUMAN; INCIDENCE; LOW DRUG DOSE; PHYSICAL EXAMINATION; PROPHYLAXIS; RELAPSE; REVIEW; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; RISK REDUCTION; SPONDYLOARTHROPATHY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE;

AGE FACTORS; ANTIRHEUMATIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOCORTICOIDS; HUMANS; METHOTREXATE; POLYMYALGIA RHEUMATICA; PREDNISONE; RECURRENCE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77951275981     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003724739     Document Type: Review

References (86)

1. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002;347:261-271 (Pubitemid 34787634)
2. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009;61:1454-1461
3. Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 1982;97:672-680
4. Healey LA. Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin Arthritis Rheum 1984;13:322-328 (Pubitemid 14079396)
5. González-Gay MA, Rodríguez-Valverde V, Blanco R, et al. Polymyalgia rheumatica without significantly increased erythrocyte sedimentation rate. A more benign syndrome. Arch Intern Med 1997;157:317-320 (Pubitemid 27066401)
6. González-Gay MA, Amoli MM, Garcia-Porrua C, Ollier WE. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum 2003;33:38-48 (Pubitemid 37046580)
7. Gonzalez-Gay MA, Garcia-Porrua C. Epidemiology of the vasculitides. Rheum Dis Clin North Am 2001;27:729-749 (Pubitemid 33054990)
8. Salvarani C, Cantini F, Olivieri I, et al. Proximal bursitis in active polymyalgia rheumatica. Ann Intern Med 1997;127:27-31 (Pubitemid 27283900)
9. Cantini F, Salvarani C, Olivieri I, et al. Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case-control study. J Rheumatol 2001;28:1049-1055 (Pubitemid 32422588)
10. Cantini F, Niccoli L, Nannini C, et al. Inflammatory changes of hip synovial structures in polymyalgia rheumatica. Clin Exp Rheumatol 2005;23:462-468 (Pubitemid 41447615)
11. Salvarani C, Barozzi L, Cantini F, et al. Cervical interspinous bursitis in active polymyalgia rheumatica. Ann Rheum Dis 2008;67:758-761 (Pubitemid 351829374)
12. Dasgupta B, Salvarani C, Schirmer M, et al.; members of the American College of Rheumatology Work Group for Development of Classification Criteria for PMR. Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey. J Rheumatol 2008;35:270-277 (Pubitemid 351281148)
13. Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, et al. The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain. J Rheumatol 2000;27:2179-2184
14. Gonzalez-Gay MA, Garcia-Porrua C, Vazquez-Caruncho M. Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica. J Rheumatol 1998;25:1750-1755 (Pubitemid 28439269)
15. Gonzalez-Gay MA. Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. Semin Arthritis Rheum 2004;33:289-293
16. Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ, et al. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine 2005;84:269-276 (Pubitemid 41368480)
17. Gonzalez-Gay MA, Garcia-Porrua C, Miranda-Filloy JA, Martin J. Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management. Drugs Aging 2006;23:627-649 (Pubitemid 44394946)
18. González-Gay MA, García-Porr-ua C, Vázquez-Caruncho M, et al. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J Rheumatol 1999;26:1326-1332 (Pubitemid 29268086)
19. Kremers HM, Reinalda MS, Crowson CS, et al. Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol 2005;32:65-73
20. Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG. Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970 -- 1991. Arthritis Rheum 1995;38:369-373
21. Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, Hunder GG. Diagnostic approach in a patient presenting with polymyalgia. Clin Exp Rheumatol 1999;17:276-278 (Pubitemid 29265673)
22. Gonzalez-Gay M. The diagnosis and management of patients with giant cell arteritis. J Rheumatol 2005;32:1186-1188 (Pubitemid 40995367)
23. Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med 1995;123:192-194
24. Healey LA. The relation of giant cell arteritis to polymyalgia rheumatica. Baillieres Clin Rheumatol 1991;5:371-378
25. Gonzalez-Gay MA, Blanco R, Sanchez-Andrade A, Vazquez-Caruncho M. Giant cell arteritis in Lugo, Spain: a more frequent disease with fewer classic features. J Rheumatol 1997;24:2166-2170 (Pubitemid 27474039)
26. Rynes RI, Mika P, Bartholomew LE. Development of giant cell (temporal) arteritis in a patient 'adequately' treated for polymyalgia rheumatica. Ann Rheum Dis 1977;36:88-90 (Pubitemid 8038414)
27. Papadakis MA, Schwartz MD. Temporal arteritis after normalization of erythrocyte sedimentation rate. Arch Intern Med 1986;146:2283-2284
28. Gonzalez-Gay MA, Garcia-Porrua C, Rivas MJ, et al. Epidemiology of biopsy proven giant cell arteritis in northwestern Spain: trend over an 18 year period. Ann Rheum Dis 2001;60:367-371 (Pubitemid 32242750)
29. Rodriguez-Valverde V, Sarabia JM, González-Gay MA, et al. Risk factors and predictive models of giant cell arteritis in polymyalgia rheumatica. Am J Med 1997;102:331-336 (Pubitemid 27249098)
30. Caselli RJ, Hunder GG. Neurologic aspects of giant cell (temporal) arteritis. Rheum Dis Clin North Am 1993;19:941-953 (Pubitemid 23347419)
31. Gonzalez-Gay MA, Santiago J, Monte R, Blanco R. Low-dose corticosteroids and blindness in giant cell arteritis. Br J Rheumatol 1996;35:702-703 (Pubitemid 26248389)
32. Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 1998;41:1497-1504 (Pubitemid 28373132)
33. Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, et al. Polymyalgia manifestations in different conditions mimicking polymyalgia rheumatica. Clin Exp Rheumatol 2000;18:755-759 (Pubitemid 30655857)
34. Bengston B-A, Malmvall B-E. The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Incidences of different clinical presentations and eye complications. Arthritis Rheum 1981;24:899-904
35. Spiera H, DAvison S. Long-term follow-up of polymyalgia rheumatica. Mt Sinai J Med 1978;45:225-229 (Pubitemid 8362488)
36. Healey LA, Sheets PK. The relation of polymyalgia rheumatica to rheumatoid arthritis. J Rheumatol 1988;15:750-752
37. Healey LA. Polymyalgia rheumatica and seronegative rheumatoid arthritis may be the same entity. J Rheumatol 1992;19:270-272
38. Bahlas S, Ramos-Remus C, Davis P. Clinical outcome of 149 patients with polymyalgia rheumatica and giant cell arteritis. J Rheumatol 1998;25:99-104 (Pubitemid 28060126)
39. Salvarani C, Cantini F, Macchioni PL, et al. Distal musculoskeletal manifestations in polymyalgia rheumatica. Arthritis Rheum 1998;41:1221-1226 (Pubitemid 30655857)
40. Salvarani C, Gabriel S, Hunder GG. Distal extremity swelling with pitting edema in polymyalgia rheumatica. Report of nineteen cases. Arthritis Rheum 1996;39:73-80 (Pubitemid 26036380)
41. Salvarani C, Cantini F, Olivieri I, Hunder GG. Polymyalgia rheumatica: a disorder of extraarticular synovial structures. J Rheumatol 1999;26:517-521 (Pubitemid 29125564)
42. Salvarani C, Hunder GG. Musculoskeletal manifestations in a population-based cohort of patients with giant cell arteritis. Arthritis Rheum 1999;42:259-266 (Pubitemid 29268964)
43. Healey LA. Rheumatoid arthritis in the elderly. Clin Rheum Dis 1986;12:173-179
44. Ceccato F, Roverano S, Barrionuevo A, et al. The role of anticyclic citrullinated peptide antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica. Clin Rheumatol 2006;25:854-857 (Pubitemid 44473152)
45. McCarthy DJ, Oduffy JD, Pearson L, Hunter JB. Remitting seronegative symmetrical synovitis with pitting edema: RS3PE syndrome. JAMA 1985;254:2763-2767 (Pubitemid 16243296)
46. Cantini F, Salvarani C, Olivieri I, et al. Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) syndrome: a prospective follow up and magnetic resonance imaging study. Ann Rheum Dis 1999;58:230-236 (Pubitemid 29191654)
47. Dubost J-J, Sauvezie B. Late onset peripheral spondyloarthropathy. J Rheumatol 1989;16:1214-1217 (Pubitemid 19260110)
48. Olivieri I, Garcia-Porrua C, Padula A, et al. Late onset undifferentiated spondyloarthritis presenting with polymyalgia rheumatica features: description of seven cases. Rheumatol Int 2007;27:927-933 (Pubitemid 47084241)
49. Pego-Reigosa JM, Rodriguez-Rodriguez M, Hurtado-Hernandez Z, et al. Calcium pyrophosphate deposition disease mimicking polymyalgia rheumatica: a prospective followup study of predictive factors for this condition in patients presenting with polymyalgia symptoms. Arthritis Rheum 2005;5:931-938 (Pubitemid 41811135)
50. Hutton CW, Maddison PJ. Systemic lupus erythematosus presenting as polymyalgia rheumatica in the elderly. Ann Rheum Dis 1986;45:641-644 (Pubitemid 16038563)
51. Maragou M, Siotsiou F, Sfondouris H, et al. Late onset systemic lupus erythematosus presentingas polymyalgia rheumatica. Clin Rheumatol 1989;8:91-97 (Pubitemid 20115045)
52. Gonzalez-Juanatey C, González-Gay MA, Llorca J, et al. Rheumatic manifestations of infective endocarditis in non-addicts: a 12-year study. Medicine 2001;80:9-19 (Pubitemid 32066375)
53. Churchill MA, Geraci HJE, Hunder GG. Musculoskeletal manifestations of bacterial endocarditis. Ann Intern Med 1977;87:754-759
54. Gonzalez-Gay MA, Garcia-Porrua C, Ibañez D, Garcia-Pais MJ. Osteoarticular complications of brucellosis in an Atlantic area of Spain. J Rheumatol 1999;26:141-145 (Pubitemid 29051410)
55. Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol 2002;29:2143-2147
56. Gonzalez-Gay MA, Lopez-Diaz MJ, Martinez-Lado L, et al. Cancer in biopsy-proven giant cell arteritis. A population-based study. Semin Arthritis Rheum 2007;37:156-163 (Pubitemid 350151504)
57. Naschitz SE, Resner I, Rozenbaum M, et al. Cancer-associated rheumatic disorders. Semin Arthritis Rheum 1995;24:231-241
58. Kalra L, Delamere JP. Lymphoreticular malignancy and monoclonal gammopathy presenting as polymyalgia rheumatica. Br J Rheumatol 1987;26:458-459 (Pubitemid 18005355)
59. Ilfeld D, Barzilay J, Vana D, et al. IgG monoclonal gammopathy in four patients with polymyalgia rheumatica. Ann Rheum Dis 1985;44:501
60. von Knorring J. Polymyalgia rheumatica and malignant lymphoma: report on a case. Scand J Rheumatol 1972;1:117-120
61. Sahin M, Alanoglu G, Aksu O, et al. Hodgkin's lymphoma initially presenting with polymyalgic symptoms: a case report. Mod Rheumatol 2007;17:160-162 (Pubitemid 46614363)
62. Sheon RP, Kirsner AB, Tangsintanapas P, et al. Malignancy in rheumatic disease: interrelationships. J Am Geriatr Soc 1977;25:20-27 (Pubitemid 8017091)
63. Von Knorring J, Somer T. Malignancy in association with polymyalgia rheumatica and temporal arteritis. Scand J Rheumatol 1974;3:129-135
64. Sidhom OA, Basalaev M, Sigal LH. Renal cell carcinoma presenting as polymyalgia rheumatica: resolution after nephrectomy. Arch Intern Med 1993;153:2043-2045 (Pubitemid 23263567)
65. Salvarani C, Gabriel SE, Gertz MA, et al. Primary systemic amyloidosis presenting as giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 1994;37:1621-1626 (Pubitemid 24345810)
66. Hernández-Rodríguez J, Cid MC, López-Soto A, et al. Treatment of polymyalgia rheumatica. A systematic review. Arch Intern Med 2009;169:1839-1850
67. Hutchings A, Hollywood J, Lamping DL, et al. Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis Rheum 2007;57:803-809 (Pubitemid 46932086)
68. Dasgupta B, Dolan AL, Panayi GS, Fernandes L. An initially double-blind controlled 96-week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br J Rheumatol 1998;37:189-195 (Pubitemid 28375189)
69. Behn AR, Perera T, Myles AB. Polymyalgia rheumatica and corticosteroids: how much for how long? Ann Rheum Dis 1983;42:374-378 (Pubitemid 13037093)
70. Kyle V, Hazleman BL. The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment. Ann Rheum Dis 1993;52:847-850 (Pubitemid 24019138)
71. Amoli MM, Shelley E, Mattey DL, et al. Intercellular adhesion molecule-1 gene polymorphisms in isolated polymyalgia rheumatica. J Rheumatol 2002;29:502-504 (Pubitemid 34202818)
72. Myklebust G, Gran JT. Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis: a prospective two-year study in 273 patients. Scand J Rheumatol 2001;30:260-267 (Pubitemid 32980337)
73. Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis, I: steroid regimens in the first two months. Ann Rheum Dis 1989;48:658-661 (Pubitemid 19201963)
74. Lund B, Egsmose C, Jorgensen S, Krogsgaard MR. Establishment of the relative anti-inflammatory potency of deflazacort and prednisone in polymyalgia rheumatica. Calcif Tissue Int 1987;41:316-320
75. Di Munno O, Imbimbo B, Mazzantini M, et al. Deflazacort versus methylprednisolone in polymyalgia rheumatica: clinical equivalence and relative antiinflammatory potency of different treatment regimens. J Rheumatol 1995;22:1492-1498
76. Krogsgaard MR, Lund B, Johnsson B. A longterm prospective study of the equipotency between deflazacort and prednisolone in the treatment of patients with polymyalgia rheumatica. J Rheumatol 1995;22:1660-1662
77. Salvarani C, Cantini F, Olivieri I, et al. Corticosteroid injections in polymyalgia rheumatica: a double-blind, prospective, randomized, placebo controlled study. J Rheumatol 2000;27:1470-1476 (Pubitemid 30354047)
78. Van der Veen MJ, Dinant HJ, van Booma-Frankfort C, et al. Can methotrexate be used as a steroid-sparing agent in thetreatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 1996;55:218-223 (Pubitemid 26120700)
79. Caporali R, Cimmino MA, Ferraccioli G, et al; Systemic Vasculitis Study Group of the Italian Society for Rheumatology. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2004;141:493-500 (Pubitemid 39350239)
80. Ferraccioli G, Salaffi F, De Vita S, et al. Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol 1996;23:624-628 (Pubitemid 26132846)
81. De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986;45:136-138 (Pubitemid 16162481)
82. Salvarani C, Cantini F, Niccoli L, et al. Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study. J Rheumatol 2003;30:760-763 (Pubitemid 36402770)
83. Migliore A, Massafra U, Carloni E, et al. TNF-alpha blockade induce clinical remission in patients affected by polymyalgia rheumatica associated to diabetes mellitus and/or osteoporosis: a seven cases report. Eur Rev Med Pharmacol Sci 2005;9:373-378 (Pubitemid 43180328)
84. Gabriel SE, Sunku J, Salvarani C, et al. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 1997;40:1873-1878 (Pubitemid 27452540)
85. Sambrook PN. How to prevent steroid induced osteoporosis. Ann Rheum Dis 2005;64:176-178
86. Oxlund H, Ortoft G, Thomsen JS, et al. The anabolic effect of PTH on bone is attenuated by simultaneous glucocorticoid treatment. Bone 2006;39:244-252 (Pubitemid 43851361)